DEF 14A: Humana Faces Medical Cost Headwinds Despite Membership Growth; Board Seeks Officer Liability Protection and Streamlined Voting

Humana's 2024 proxy statement reveals a challenging 2023 marked by unexpected medical cost increases, alongside proposals to amend the company's charter regarding officer liability and voting requirements.

Summary

• Humana's 2023 was a dynamic year, marked by significant increases in medical cost trends within the Medicare Advantage (MA) industry.
• Despite efforts to offset these trends through cost discipline and productivity initiatives, the company's earnings growth failed to meet expectations.
• However, Humana achieved strong growth in individual MA membership, increasing by over 840,000 members, and maintained its leadership in member-first initiatives, with 94% of members in plans rated 4 stars or higher.
• The company also saw continued organic Medicaid growth, implementing contracts in Ohio and Louisiana in 2023 and expanding to Indiana and Oklahoma in 2024.
• CenterWell primary care expanded to nearly 300 centers serving over 294,000 patients, with year-over-year growth of 26% and 19%, respectively.
• The company's value-based home care models now cover 843,500 MA members under a value-based payment model.
• The proxy statement outlines six proposals for stockholder vote, including the election of directors, ratification of the accounting firm, executive compensation approval, and amendments to the company's charter.
• The Board recommends voting for all director nominees, ratifying PricewaterhouseCoopers, approving executive compensation, and approving the charter amendments regarding officer liability and supermajority voting, while voting against the stockholder proposal on simple majority vote.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While highlighting positive growth in membership and strategic initiatives, it acknowledges financial underperformance due to rising medical costs. The forward-looking statements are cautiously optimistic.

Positives

• Strong growth in individual Medicare Advantage membership, increasing by over 840,000 members.
• High Star Ratings performance, with 94% of Medicare Advantage members in plans rated 4 stars or higher.
• Continued organic Medicaid growth with new contracts in multiple states.
• Expansion of CenterWell primary care and value-based home care models.
• Proposed charter amendment to limit officer liability, potentially attracting and retaining talented executives.
• Proposed charter amendment to eliminate supermajority voting requirements, streamlining corporate governance.

Negatives

• Significant and unanticipated increase in medical cost trends in the Medicare Advantage (MA) industry.
• 2023 earnings growth failed to meet expectations due to the aforementioned medical cost trends.

Risks

• The company faces a complex and dynamic period of change in the Medicare Advantage industry.
• Continued increases in medical cost trends could impact future financial performance.
• The company operates in an increasingly competitive environment.
• Failure to adapt to changing market dynamics and regulatory requirements could negatively impact the company's performance.

Future Outlook

The company remains focused on margin recovery and advancing its industry-leading MA and senior-focused value-based care platforms to position the company for long-term success.

Management Comments

• Like you, we were disappointed in the Company's closing financial performance.
• Still, we do not want this setback to overshadow the advancement of our long-term strategy in 2023 achieving strong growth in our individual MA, Medicaid and CenterWell businesses, progress made across the enterprise to grow our industry leading MA and senior focused value-based care platforms and maintain our industry leading quality and customer satisfaction scores to name just a few.
• As the Company continues to navigate a complex and dynamic period of change in the MA industry in the near-term, we still believe in the strong fundamentals and significant value proposition of MA and remain focused on both margin recovery and advancing our industry leading MA and senior focused value-based care platforms to position the Company for long-term success.

Industry Context

The announcement highlights the challenges and opportunities within the evolving Medicare Advantage landscape, including the impact of medical cost trends and the importance of value-based care models.

Comparison to Industry Standards

• Humana's individual MA membership growth exceeded the industry average, with a three-year compound annual growth rate of 11%.
• Humana remained the industry leader in Star Ratings among its publicly traded peers for the sixth consecutive year.
• The document references several competitors and peers, including Centene Corporation, CVS Health Corp, Elevance Health, Inc., The Cigna Group, and UnitedHealth Group Inc.

Corporate Governance

Related Party Transactions

• The company had an agreement with BlackRock, Inc., a greater than 5% stockholder, for fixed income investment management services, for which the company paid approximately $5.43 million in fees for the year ended December 31, 2023.

Stakeholder Impact

• Stockholders: The company's financial performance and strategic decisions directly impact stockholder value.
• Members: The company's focus on member-first initiatives and value-based care aims to improve health outcomes and satisfaction.
• Employees: The company's compensation and benefits programs are designed to attract and retain talented employees.
• Communities: The company's community engagement and health equity initiatives aim to improve the health and well-being of the communities it serves.

Next Steps

• Stockholders are encouraged to vote on the six proposals outlined in the proxy statement.
• The company will continue to focus on margin recovery and advancing its value-based care platforms.
• The company will implement contracts in Indiana and Oklahoma in 2024.

Key Dates

Keywords

Medicare Advantage, CenterWell, Medicaid, Corporate Governance, Executive Compensation, Director Election, Proxy Statement, Humana, Medical Costs, Star Ratings